
Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma's Energy-Based Technology
CAESAREA, Israel, June 18, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature Portfolio, presents compelling clinical evidence on the effectiveness of non-invasive energy-based technology for abdominal fat reduction. The study demonstrated statistically significant decreases in abdominal fat layer thickness in Korean women with abdominal obesity, following a series of ultrasound and radiofrequency treatments using Alma's Accent Prime platform.
Conducted at Ewha Womans University Seoul Hospital by Dr. Yeo Ju Sohn and Dr. Hyejin Chun of the Department of Family Medicine at Ewha Womans University College of Medicine, the research confirmed measurable fat layer reduction through ultrasound imaging and waist circumference assessments. Patients reported high satisfaction and consistently strong tolerance throughout the treatment protocol, with no adverse events observed.
This publication comes at a time when abdominal obesity is increasingly recognized as a key contributor to cardiovascular disease and metabolic syndrome, both in South Korea and globally. According to the World Health Organization, more than 1 billion people worldwide are living with obesity—a major risk factor for type 2 diabetes, cardiovascular disease, and premature mortality. As obesity rates continue to rise, so does the urgency for safe, effective, and accessible treatment options beyond surgical intervention.
"This study highlights the evolving role of non-invasive modalities in body shaping and reinforces their potential significance in the broader context of health and wellness," said Lior Dayan, CEO of Alma. "This new publication strengthens the scientific foundation supporting Alma's technologies and showcases our commitment to advancing innovation that prioritizes patient safety, enhances the treatment experience, and keeps pace with the evolving needs of modern patients."
Accent Prime combines proprietary ultrasound and radiofrequency technologies to deliver personalized, non-invasive treatments for body contouring, skin tightening, and facial rejuvenation. The platform is CE marked and approved for the treatment of various different indications, including facial and body contouring, skin tightening, cellulite reduction, and skin rejuvenation. Widely adopted by leading clinics worldwide, Accent Prime offers flexible, combination-based protocols that support tailored treatment strategies across diverse skin types and body areas—without the need for surgery or downtime. These proprietary ultrasound and radiofrequency technologies have also been clinically validated in other products from Alma's Body Contouring series, such as Alma PrimeX.
Alma is a global leader in medical aesthetic solutions, with over 25 years of innovation. We empower practitioners to deliver safe, effective, and life-transforming treatments to their patients, utilizing state-of-the-art, clinically proven solutions such as energy-based device lasers, diagnostics, injectables, and advanced skincare. Alma's multiple award-winning products have set a new benchmark in the medical aesthetic industry, both in terms of clinical excellence and groundbreaking innovations.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Korea Herald
8 hours ago
- Korea Herald
Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma's Energy-Based Technology
CAESAREA, Israel, June 18, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature Portfolio, presents compelling clinical evidence on the effectiveness of non-invasive energy-based technology for abdominal fat reduction. The study demonstrated statistically significant decreases in abdominal fat layer thickness in Korean women with abdominal obesity, following a series of ultrasound and radiofrequency treatments using Alma's Accent Prime platform. Conducted at Ewha Womans University Seoul Hospital by Dr. Yeo Ju Sohn and Dr. Hyejin Chun of the Department of Family Medicine at Ewha Womans University College of Medicine, the research confirmed measurable fat layer reduction through ultrasound imaging and waist circumference assessments. Patients reported high satisfaction and consistently strong tolerance throughout the treatment protocol, with no adverse events observed. This publication comes at a time when abdominal obesity is increasingly recognized as a key contributor to cardiovascular disease and metabolic syndrome, both in South Korea and globally. According to the World Health Organization, more than 1 billion people worldwide are living with obesity—a major risk factor for type 2 diabetes, cardiovascular disease, and premature mortality. As obesity rates continue to rise, so does the urgency for safe, effective, and accessible treatment options beyond surgical intervention. "This study highlights the evolving role of non-invasive modalities in body shaping and reinforces their potential significance in the broader context of health and wellness," said Lior Dayan, CEO of Alma. "This new publication strengthens the scientific foundation supporting Alma's technologies and showcases our commitment to advancing innovation that prioritizes patient safety, enhances the treatment experience, and keeps pace with the evolving needs of modern patients." Accent Prime combines proprietary ultrasound and radiofrequency technologies to deliver personalized, non-invasive treatments for body contouring, skin tightening, and facial rejuvenation. The platform is CE marked and approved for the treatment of various different indications, including facial and body contouring, skin tightening, cellulite reduction, and skin rejuvenation. Widely adopted by leading clinics worldwide, Accent Prime offers flexible, combination-based protocols that support tailored treatment strategies across diverse skin types and body areas—without the need for surgery or downtime. These proprietary ultrasound and radiofrequency technologies have also been clinically validated in other products from Alma's Body Contouring series, such as Alma PrimeX. Alma is a global leader in medical aesthetic solutions, with over 25 years of innovation. We empower practitioners to deliver safe, effective, and life-transforming treatments to their patients, utilizing state-of-the-art, clinically proven solutions such as energy-based device lasers, diagnostics, injectables, and advanced skincare. Alma's multiple award-winning products have set a new benchmark in the medical aesthetic industry, both in terms of clinical excellence and groundbreaking innovations.
![[Bio USA] GI Innovation unveils next-gen immunotherapy pipeline](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F18%2Fnews-p.v1.20250618.d08a9f94aea74f3da95329681a945806_T1.jpg&w=3840&q=100)
![[Bio USA] GI Innovation unveils next-gen immunotherapy pipeline](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fkoreaherald.com.png&w=48&q=75)
Korea Herald
12 hours ago
- Korea Herald
[Bio USA] GI Innovation unveils next-gen immunotherapy pipeline
BOSTON -- Korean biotech company GI Innovation showcased its next-generation growth strategy at Bio USA 2025 in Boston on Tuesday. Leading the presentation was Yun Nari, head of GI Innovation's clinical strategy, who introduced the company's new drug development pipeline and global business roadmap. A licensed pharmacist, Yun joined the company's board of directors in March and is expected to play a pivotal role in accelerating clinical decision-making, an essential function in GI Innovation's core business of clinical-stage drug development. A key highlight was the unveiling of GI-128, a novel immuno-oncology candidate that leverages macrophage engagement, an emerging target in next-generation cancer therapies. The company also spotlighted its trispecific antibody pipeline, designed to surpass the current generation of aPD-(L)1/VEGF bispecific antibodies, which are gaining significant traction in the global oncology space. 'This year's Bio USA is a premier platform that brings together leading global investors and pharmaceutical companies,' said Jang Myoung-ho, CEO and founder of GI Innovation. 'It presented the perfect opportunity to demonstrate the competitiveness of our pipeline and global expansion strategy. We plan to actively explore a variety of partnership opportunities, including technology licensing, co-development deals and strategic investments.' Meanwhile, the growing interest in aPD-(L)1/VEGF bispecific antibodies in the immuno-oncology sector has led to a surge in high-value deals. Bristol Myers Squibb recently entered into a licensing agreement with German biotech firm BioNTech, paying an upfront sum of approximately $1.5 billion, with the total deal valued at around $11.1 billion. Likewise, Merck & Co. signed a deal last year with China-based LaNova Medicines, worth $588 million upfront and up to $2.7 billion in milestone payments. Building on this trend, GI Innovation's trispecific antibody platform integrates the company's proprietary aPD-L1 antibody, a VEGF antibody and a macrophage engager into a single molecule. The design aims to overcome the therapeutic limitations of bispecific antibodies by stimulating a more robust immune response within the tumor microenvironment, the company explained.


Korea Herald
13 hours ago
- Korea Herald
Angel Yeast Marks Sustainable Gastronomy Day with Outstanding Results in Weight Management Year
YICHANG, China, June 18, 2025 /PRNewswire/ -- Angel Yeast (SH:600298), a global leader in yeast manufacturing, is celebrating Sustainable Gastronomy Day (June 18) by promoting low-carbon healthy diet solutions as part of its ongoing mission to reshape the nutritional health landscape. This initiative expands on the company's "Weight Management Year" program introduced at Yichang's National Nutrition Week opening ceremony (May 17, 2025). Centered on the innovative theme "The Awakening of Yeast Power," the campaign masterfully blended nutritional science with engaging public demonstrations, highlighting yeast's unique benefits for metabolic health and weight management. Among Angel Yeast's key innovations is AngeoPro® yeast protein, a decade-long research breakthrough that addresses global protein shortages while contributing to the achievement of China's "Dual Carbon" goals. According to the "World Obesity Atlas 2025" released by the World Obesity Federation, the number of obese adults worldwide is projected to increase from 524 million in 2010 to 1.13 billion by 2030—an increase of over 115 percent. This stark projection accentuates on the growing trend of obesity and its potential threats to public health, and the urgency for taking proactive measures. Effective weight management is crucial for preventing diseases such as hypertension and diabetes and improving quality of life. In response to the global challenge, Angel Yeast launched the "Weight Management Year" initiative in May 2024. Since then, the program has engaged 15,000 people with nearly 1,000 active participants, 70 percent of whom lost weight successfully, averaging at 1 kilogram per person. "The foundation of effective weight management is maintaining a balanced diet and physical activity, Angel Yeast has innovatively developed a range of products, including yeast protein, low-sodium yeast extract seasonings and low-sugar soft bread, leveraging advanced technologies to reduce salt, oil and sugar to bring a more science-based and efficient approach of weight management," said Zhang Yan, chief engineer of Angel Yeast. Yeast is a type of probiotic, and the yeast protein has been shown to significantly alleviate the histological and functional degradation of intestinal health caused by aging. Additionally, it enhances the microbial population of intestinal tract and promoting overall gut health. The AngeoPro® yeast protein is non-animal derived, environmentally friendly, safe and nutritionally rich, and has emerged as a strong option of protein, contributing to improving the global protein supply and advancing sustainable development. Currently, the use of yeast protein in the global food industry is experiencing a steady annual increase. Yeast protein has become a fundamental component of daily diets, driving a shift towards healthier eating habits. "Yeast protein boasts a complete set of amino acids – including all nine essential amino acids needed by the human body, and its composition closely aligns with the ideal amino acid profile recommended by the Food and Agriculture Organization (FAO). With a digestion and absorption rate of up to 90 percent and a biological value of 87, its amino acid score adjusted for digestibility (PDCAAS) is equal to 1, surpassing soy protein and matches whey protein, making it a highly valuable source of quality nutrition," noted Zhang. Yeast protein also contains a high content of lysine, making it particularly suitable for groups whose main source of food is grains, as nutritional yeast protein powder is also rich in B vitamins. AngeoPro® yeast protein can increase the abundance of Bacteroides the taiotaomicron in the gut, which may enhance the body's metabolic efficiency and positively impact weight management. The use of yeast protein in global food industry is increasing steadily and has become a fundamental component of daily diets to drive a shift towards healthier eating routines. As research continues to advance, the functional applications of AngeoPro® yeast protein are being further explored in areas such as muscle reconstruction, sports injuries recovery, digestive health, immune support, and lipid metabolism. Moving forward, Angel Yeast is committed to continuously promoting the global application of yeast protein, contributing to healthier and more sustainable diets and lifestyles.